Although the immunogenicity of FYN has not been experimentally proven, its prognostic impact on a variety of tumors is obvious, such as breast cancer (Xie et al., 2016), pancreatic cancer (Dong et al., 2020). This evidence concerns the gene FYN and breast carcinoma.